{"filings":[{"id":1480278,"accession_number":"0001193125-26-296710","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-07-07T01:55:41+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.","$4.5B bridge loan facility from Bank of America and Morgan Stanley backs the deal; no financing condition.","Crinetics stockholders must approve; HSR and foreign regulatory clearances required; termination fee of $350M.","Vertex expects deal to accelerate revenue growth, with potential >$5B annual revenue; accretive to non-GAAP op income by 2029.","Crinetics' pipeline includes PALSONIFY (acromegaly) and atumelnant (CAH); Vertex sees significant commercial potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67883,"accession_number":"0000875320-26-000204","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-05-13T20:03:13+00:00","items":["5.02","5.07"],"status":"ready","headline":"Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.","Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).","Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.","2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.","Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99331,"accession_number":"0000875320-26-000171","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.","CASGEVY revenue $43M; JOURNAVX revenue $29M; non-CF products drove >25% of growth.","Completed rolling BLA submission for povetacicept in IgAN for U.S. accelerated approval; Priority Review Voucher expected to expedite review to 6 months.","Terminated VX-522 (CF) Phase 1/2 due to persistent tolerability issues; no efficacy readout possible.","FY2026 guidance reiterated: revenue $12.95-13.1B, combined R&D/SG&A unchanged."],"consensus_eps_estimate":4.3964,"consensus_eps_actual":4.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":2986900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99330,"accession_number":"0000875320-26-000166","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vertex director Suketu Upadhyay to depart after annual meeting to become Incyte CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Upadhyay will not stand for re-election due to scheduling conflicts from his incoming CFO role at Incyte.","He will continue as director until the 2026 annual meeting; board reduces size to ten members.","Proxy materials amended to remove Upadhyay as nominee; previously voted proxies remain valid for other matters.","Departure is not due to any disagreement with Vertex on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115268,"accession_number":"0000875320-26-000147","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vertex completes BLA submission for povetacicept in IgAN with priority review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted rolling Biologics Licensing Application to FDA for povetacicept to treat IgAN in adults.","Used a priority review voucher, reducing expected FDA review to 6 months from typical 10 months.","Submission seeks potential accelerated approval; no decision or timeline for acceptance yet.","Company notes forward-looking statements and risks including regulatory approval uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115267,"accession_number":"0000875320-26-000034","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.","GAAP net income $4.0B in FY2025 vs net loss of $(536)M in 2024; cash $12.3B.","FY2026 revenue guidance $12.95–$13.1B; non-CF product revenue expected ≥$500M.","JOURNAVX: >550,000 prescriptions filled in 2025; coverage for >200M U.S. lives.","Rolling BLA for povetacicept in IgAN on track for completion in H1 2026; ALYFTREK pediatric study completed."],"consensus_eps_estimate":5.1744,"consensus_eps_actual":15.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":12001300000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131683,"accession_number":"0000875320-25-000230","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.","FY2025 revenue guidance raised to $11.9-12.0B; non-GAAP OpEx guidance $5.0-5.1B; tax rate lowered to 17-18%.","Povetacicept Phase 3 IgAN enrollment complete; first BLA module submission to FDA by end of 2025.","JOURNAVX: >300K prescriptions since March; CASGEVY: 165 cell collections, 39 infusions globally.","Zimislecel T1D trial enrollment complete; dosing temporarily postponed pending manufacturing analysis."],"consensus_eps_estimate":4.6547,"consensus_eps_actual":10.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":8811300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148251,"accession_number":"0000875320-25-000213","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B","Reiterated FY25 revenue guidance $11.85-$12.0B; combined R&D/SG&A guidance unchanged","CSO David Altshuler to retire Aug 1, 2026; Mark Bunnage becomes CSO effective Feb 1, 2026 as planned transition","VX-993 Phase 2 acute pain study missed primary endpoint; Vertex not advancing it as monotherapy","CASGEVY: ~115 patients had first cell collection, 29 infused; JOURNAVX: >110,000 prescriptions filled"],"consensus_eps_estimate":4.3693,"consensus_eps_actual":6.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":5734900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167023,"accession_number":"0000875320-25-000199","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vertex Pharmaceuticals authorizes $4.0B share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.","Combined with ~$775M remaining under 2023 program, total authorization rises to ~$4.775B.","Repurchases may be made on open market or private transactions, including under Rule 10b5-1 plans.","Company can discontinue program at any time; repurchases subject to market conditions and other opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167022,"accession_number":"0000875320-25-000194","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vertex shareholders elect all 11 directors, reject golden parachute proposal at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with majority support; Bruce Sachs received lowest 'for' votes at 211.6M.","Ratification of Ernst & Young as auditor for FY2025 passed with 229.4M votes for, 6.9M against.","Advisory vote on 2024 named executive officer compensation approved: 208.9M for, 17.0M against.","Shareholder proposal on excessive golden parachutes rejected: 84.1M for, 141.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167021,"accession_number":"0000875320-25-000171","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q1 revenue $2.77B (+3% YoY); GAAP net income falls to $646M on $379M impairment; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.","GAAP net income $646M vs $1.1B Q1 2024; includes $379M impairment charge on discontinued VX-264 T1D program.","Non-GAAP net income $1.1B vs $1.2B; combined non-GAAP R&D, AIPR&D and SG&A expenses $1.2B.","Raised FY2025 revenue guidance low end to $11.85B-$12B (from $11.75B-$12B); reiterates expense guidance.","JOURNAVX launch: >20,000 prescriptions filled since March; ~94M lives have covered access."],"consensus_eps_estimate":null,"consensus_eps_actual":2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":2770200000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184401,"accession_number":"0000875320-25-000156","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.","Vertex expects non-cash impairment charge of ~$400M from VX-264 intangible assets in Q1 and FY 2025.","Preliminary analysis; Vertex will disclose final impairment results in Q1 2025 Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184400,"accession_number":"0000875320-25-000029","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.","GAAP net loss $536M for 2024 due to $4.4B AIPR&D from Alpine Immune Sciences acquisition; non-GAAP net income $111M.","FY2025 total revenue guidance $11.75-12.0B; combined non-GAAP R&D, AIPR&D, SG&A expenses guided at $4.9-5.0B.","COO Stuart Arbuckle retiring July 1, 2025; CFO Charlie Wagner to add COO role, Duncan McKechnie to become CCO.","JOURNAVX approved Jan 30, 2025 for moderate-to-severe acute pain; ALYFTREK approved Dec 20, 2024 for CF ages 6+."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":11020100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201000,"accession_number":"0000875320-24-000231","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.","Annual wholesale acquisition cost in the U.S. is $370,269 ($28,404 per 28-day pack).","Approval expands Vertex's cystic fibrosis treatment portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200999,"accession_number":"0000875320-24-000221","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.","FY 2024 product revenue guidance raised to $10.8-10.9B from $10.65-10.85B.","PDUFA dates: vanzacaftor triple Jan 2, 2025; suzetrigine Jan 30, 2025; both Priority Review.","Three programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, VX-880 in T1D.","CASGEVY revenue from first infused patient; 45 ATCs activated globally."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":8108100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217007,"accession_number":"0000875320-24-000207","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vertex extends Boston headquarters leases to 2044, adding renewal options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended combined ~1.1 million sq ft of office and lab space under two leases in Boston.","Lease term extended from December 2028 to June 30, 2044, with options for two additional ten-year periods.","Amendments signed with SNH Seaport LLC on August 15, 2024.","Previous lease had a single 10-year extension option; new terms provide up to 20 additional years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217006,"accession_number":"0000875320-24-000193","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.","Non-GAAP net loss of $3.3B; combined R&D and SG&A expenses increased to $1.3B.","FDA accepted NDAs for vanzacaftor triple (PDUFA Jan 2, 2025) and suzetrigine (PDUFA Jan 30, 2025).","CASGEVY launches ongoing; >35 ATCs activated; early access program in France for SCD.","Year-end cash $10.2B vs $13.7B end of 2023; cash used for Alpine acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":5336200000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236764,"accession_number":"0000875320-24-000178","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.","Also expects $200M transaction-related compensation expense for acceleration of unvested Alpine equity awards in Q2 2024.","Charges will impact GAAP and non-GAAP operating expenses and net income for Q2 and full year 2024, and related guidance.","Vertex completed Alpine acquisition for $5.0B cash on May 20, 2024; expects to absorb Alpine's non-GAAP R&D/SG&A within existing guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236763,"accession_number":"0001193125-24-142278","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Alpine for approximately $5.0B in equity value completed.","Alpine now operates as a wholly owned subsidiary of Vertex.","Accounting treatment for the acquisition to be finalized during Q2 2024.","Merger effected via tender offer followed by a Section 251(h) merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236762,"accession_number":"0000875320-24-000142","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vertex Pharmaceuticals Shareholders Elect Directors and Approve Proposals at Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 11 board nominees, including Reshma Kewalramani and Jeffrey Leiden, with each receiving over 217 million votes for.","Ratification of Ernst & Young as independent auditor for FY2024 approved with 229,460,523 votes for, 3,987,619 against.","Advisory vote on 2023 executive compensation program passed with 202,098,575 votes for, 19,223,784 against.","Shareholder proposal for special shareholder meeting improvement approved with 160,438,357 votes for, 61,494,550 against.","Shareholder proposal on racial and gender pay gaps report did not pass, receiving only 63,865,687 for vs 157,637,997 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236761,"accession_number":"0000875320-24-000137","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.","Reiterates FY2024 product revenue guidance $10.55-$10.75B; combined non-GAAP R&D and SG&A $4.3-$4.4B.","Submitted NDA (priority review) for vanzacaftor triple in CF to FDA and MAA to EMA; rolling NDA for suzetrigine in acute pain.","Entered agreement to acquire Alpine Immune Sciences for ~$4.9B ($65/sh cash); expected close Q2 2024.","Cash and marketable securities $14.6B; >25 CASGEVY ATCs activated globally; multiple patients started cell collection."],"consensus_eps_estimate":null,"consensus_eps_actual":4.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2690600000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236760,"accession_number":"0001193125-24-092475","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vertex to acquire Alpine Immune Sciences for $65 per share in all-cash tender offer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vertex agrees to buy Alpine Immune Sciences at $65/share via tender offer followed by a merger.","Supporting stockholders owning ~25.5% of Alpine shares have committed to tender their shares.","Alpine must pay Vertex a $173M termination fee if deal terminates under specified conditions.","Offer is not subject to a financing condition; expected to close by April 10, 2025 outside date.","Deal includes full vesting of unvested equity awards, which will be cashed out at the offer price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254376,"accession_number":"0000875320-24-000012","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).","FY24 product revenue guidance $10.55-$10.75B, reflecting CF growth and CASGEVY launch.","Completed pivotal studies for vanzacaftor triple (CF) and VX-548 (acute pain); NDAs to FDA by mid-2024.","CASGEVY approved in U.S., Great Britain, KSA, Bahrain; CHMP positive opinion; activated ATCs.","VX-880 Phase 1/2 study on protocol-specified pause; VX-264 advanced to Part B."],"consensus_eps_estimate":null,"consensus_eps_actual":13.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":9869200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271868,"accession_number":"0000875320-23-000054","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.","Wholesale acquisition cost (WAC) set at $2.2 million.","CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271867,"accession_number":"0000875320-23-000047","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vertex appoints Nancy Thornberry to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nancy Thornberry, former CEO of Kallyope and ex-Merck executive, joins the board effective December 5, 2023.","Board size increased from 10 to 11 members with Thornberry's appointment.","Thornberry received a $400,000 restricted stock unit award vesting in December 2024.","No related party transactions or arrangements with any other persons were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271866,"accession_number":"0000875320-23-000029","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).","FY2023 product revenue guidance raised to ~$9.85B (from $9.7-9.8B); opex guidance unchanged.","Exa-cel PDUFA for SCD Dec 8, 2023; BLA Priority Review; EU/UK reviews ongoing.","Phase 3 data for vanzacaftor triple and VX-548 acute pain expected early 2024; Phase 2 neuropathic pain data late 2023.","Cash and marketable securities $13.6B at Sep 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":10.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":7351500000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271865,"accession_number":"0000875320-23-000023","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vertex appoints Michel Lagarde to board as tenth director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michel Lagarde appointed to Vertex board effective Oct 5, 2023; board expands to 10.","Lagarde is EVP and COO of Thermo Fisher Scientific; background in pharma services and private equity.","Received $400,000 RSU award vesting in October 2024; standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288711,"accession_number":"0000875320-23-000019","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).","Full-year CF product revenue guidance raised to $9.7-$9.8B from $9.55-$9.7B; R&D/SG&A guidance also raised.","FDA accepted exa-cel BLAs for SCD & TDT; Priority Review for SCD, PDUFA Dec 8, 2023; TDT PDUFA Mar 30, 2024.","Vanzacaftor triple SKYLINE & RIDGELINE studies expected to complete by end of 2023; results in early 2024.","VX-548 pivotal program in acute pain expected to complete late 2023; results late 2023/early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":6.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":4868000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309350,"accession_number":"0000875320-23-000015","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vertex shareholders elect all nine director nominees at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; votes ranged from 203.8M to 223.0M in favor.","Ernst & Young ratified as independent auditor for 2023: 226.5M for, 7.8M against.","Advisory approval of 2022 executive compensation passed with 200.9M for (~89% of votes cast).","Shareholders recommended annual frequency for future advisory votes (222.8M for 1 year); board adopts annual schedule.","Non-votes on director election, compensation, and frequency proposals were 9.8M shares (broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309349,"accession_number":"0000875320-23-000010","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q1 product rev $2.37B (+13%); net income down 8% on higher R&D; FY23 guidance unchanged","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.37B (+13% YoY); U.S. $1.40B (+3%), ex-U.S. $971M (+33%).","GAAP net income decreased 8% YoY; cash and marketable securities $11.5B at quarter end.","FY23 product revenue guidance reaffirmed at $9.55-9.7B; combined GAAP R&D and SG&A unchanged at $4.35-4.6B.","TRIKAFTA approved in U.S. for CF children aged 2-5; completed rolling BLA submissions for exa-cel in U.S.","Pipeline: VX-548 acute pain Phase 3 enrollment ongoing; inaxaplin AMKD Phase 2/3; VX-880 T1D data expected at ADA June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":2.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":2374800000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328076,"accession_number":"0000875320-23-000004","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.","Q4 product revenue $2.30B (+11% YoY); GAAP diluted EPS $3.15, non-GAAP $3.76.","FY2023 product revenue guidance of $9.55B-$9.7B, implying 7-9% growth.","Exa-cel regulatory submissions validated in EU and UK; US rolling BLA underway.","CF drug TRIKAFTA/KAFTRIO generated $7.69B in FY22, up 35% from $5.70B in FY21."],"consensus_eps_estimate":null,"consensus_eps_actual":12.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":8930700000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345733,"accession_number":"0000875320-22-000036","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.","GAAP diluted EPS $3.59; non-GAAP diluted EPS $4.01, up 14% YoY.","Full-year 2022 product revenue guidance raised to $8.8-8.9B from prior $8.6-8.7B.","Initiating global regulatory submissions for exa-cel (sickle cell/beta thalassemia) in 2022; Phase 3 for VX-548 (acute pain) started.","Cash and marketable securities $11.5B as of Sept 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":9.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6628000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362146,"accession_number":"0000875320-22-000026","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.","GAAP diluted EPS $3.13; non-GAAP diluted EPS $3.60.","Raised full-year 2022 product revenue guidance to $8.6-$8.8B from prior $8.4-$8.6B.","Clinical updates: exa-cel (sickle cell/beta thalassemia) and VX-880 (type 1 diabetes) data demonstrate transformative potential."],"consensus_eps_estimate":null,"consensus_eps_actual":6.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":4293700000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362145,"accession_number":"0000875320-22-000022","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.","Goal is to accelerate development of VX-880, Vertex's investigational stem cell-derived islet therapy for T1D.","ViaCyte brings complementary tools: stem cell lines, IP, GMP manufacturing, and hypoimmune assets via CRISPR collaboration.","Acquisition expected to close later this year, subject to HSR waiting period and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362144,"accession_number":"0000875320-22-000019","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-07-05T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Vertex enters new $500M senior unsecured revolving credit facility, replaces 2019 agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M revolving facility, matures July 1, 2027; capacity can be increased by an additional $500M.","Interest: base rate +0.000%-0.500% or SOFR +1.000%-1.500%, based on leverage ratio or credit rating.","Financial covenant: consolidated leverage ratio ≤3.50:1 (4.00:1 after material acquisition).","Old 2019 credit agreement terminated and all obligations repaid; related guarantees released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381666,"accession_number":"0000875320-22-000017","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.","The transaction closed on May 19, 2022, and was disclosed in an 8-K filed May 23, 2022.","Vertex will record the $60 million purchase price in GAAP and non-GAAP operating expenses in Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381665,"accession_number":"0001193125-22-154021","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vertex shareholders elect 11 directors, approve stock plan amendment adding 13.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected, with Reshma Kewalramani receiving 218.7M votes for.","Ratification of Ernst & Young as auditor for FY2022 passed with 177.8M for, 51.9M against.","Advisory say-on-pay approved, 202.2M for vs 16.1M against.","Amendment to 2013 Stock and Option Plan adding 13.5M shares authorized for issuance approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381664,"accession_number":"0000875320-22-000011","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).","GAAP diluted EPS $2.96; Non-GAAP diluted EPS $3.52 (up 18% YoY).","Reaffirmed FY 2022 product revenue guidance $8.4-8.6B.","Pipeline spans 6 disease areas; positive Phase 2 proof-of-concept studies; more therapies entering clinic H2 2022.","Changed non-GAAP methodology; no longer exclude certain R&D milestone payments; recast prior periods."],"consensus_eps_estimate":null,"consensus_eps_actual":2.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":2097500000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399651,"accession_number":"0000875320-22-000003","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.","Q4 2021 GAAP net income $770M ($3.00 diluted EPS); Non-GAAP $866M ($3.37).","FY 2022 product revenue guidance $8.4-$8.6B; combined Non-GAAP R&D+SG&A $2.70-$2.75B.","KAFTRIO approved in EU/UK for CF children 6-11; new reimbursement agreements in Spain and Netherlands.","Pipeline: VX-147 AMKD Phase 2 POC met; VX-880 T1D Day 150 data shows insulin reduction; CTX001 enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":9.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7574400000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418642,"accession_number":"0000875320-21-000031","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.","Raised FY2021 product revenue guidance to $7.4-7.5B from prior $7.2-7.4B.","TRIKAFTA/KAFTRIO net revenues $1.556B, up 62% YoY from $960M.","Pipeline: VX-880 T1D positive data (1st patient); VX-147 Phase 2 results Q4; VX-548 data Q1 2022.","CTX001 target enrollment achieved in TDT and SCD trials; regulatory submissions planned late 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":6.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":5501839000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436195,"accession_number":"0000875320-21-000024","cik":875320,"company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.","GAAP net income $67M ($0.26 diluted EPS); non-GAAP net income $811M ($3.11 EPS).","Raised full-year 2021 product revenue guidance to $7.2-7.4B from $6.7-6.9B.","Recorded $900M payment to CRISPR in Q2 as R&D expense, impacting GAAP results.","CTX001 dosed >45 patients; target enrollment in Phase 3 studies expected Q3 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":3517675000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":110230230000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}